Review · United States
Cerebrolysin
Reviewed on
Approval and product status
Authorized in Austria; no FDA-approved Cerebrolysin product was identified in the United States as reviewed August 30, 2026
Cerebrolysin is a specific finished product made from a pig-brain-derived peptide mixture. An FDA substance record and an Austrian authorization do not make every brain hydrolysate, compounded product, or online product equivalent to Cerebrolysin.
What was measured in people?
- Health results · Moderate
- Randomized human studies include a large stroke trial and smaller dementia trials. The largest stroke trial found no significant difference on its main recovery measure.
- Body changes · Limited
- Cerebrolysin is a mixture, not one defined molecule. Its product information says researchers cannot directly track the whole mixture through the body.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
The available evidence does not define the full safety profile of every Cerebrolysin product or related mixture. The 2023 stroke review found a possible increase in serious health problems that did not cause death. This guide does not diagnose, treat, recommend, or provide product-use or sourcing instructions.
Still unknown: A 2019 Cochrane review covered six vascular-dementia studies with 597 people. Study problems made the evidence very uncertain. Any benefit might be too small to matter. One Alzheimer's study included 192 people, but it did not settle the wider question. FDA has an identity record and an orphan drug designation for Cerebrolysin. Neither means product approval. No FDA-approved U.S. product was found. Online and related brain-peptide products are not proven equal to Cerebrolysin.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Cerebrolysin is FDA-approved in the United States.”
Misleading. No FDA-approved U.S. Cerebrolysin product was identified in the reviewed approval database. An FDA substance record or orphan designation does not mean that FDA approved a product.
Applies to: United States regulatory status as reviewed August 30, 2026. Austrian authorization is a separate country status.
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
CASTA was the largest randomized stroke trial. It enrolled 1,070 adults with a stroke caused by a blocked blood vessel. Its main recovery measure found no clear difference between Cerebrolysin and placebo. A 2023 Cochrane review covered seven studies and 1,773 people. It included one study of Cortexin, a similar product. The review found no clear drop in deaths. It found a possible rise in serious health problems that did not cause death.
Read all Cerebrolysin fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 12 sources
- FDA Global Substance Registration System record for Cerebrolysin
U.S. Food and Drug Administration · Reference · 2026
Source accessed
- FDA orphan drug designation explainer
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- FDA drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Cerebrolysin Austrian product information
Austrian Federal Office for Safety in Health Care (BASG) · Drug label · 2021
Source accessed
- CASTA randomized acute stroke trial
PubMed · Stroke · Randomized trial · 2012
Source accessed
- CASTA trial record (NCT00868283)
ClinicalTrials.gov · Trial registry · 2009
Source accessed
- Cochrane review of Cerebrolysin for acute ischemic stroke
PubMed · Cochrane Database of Systematic Reviews · Science review · 2023
Source accessed
- Cochrane review of Cerebrolysin for vascular dementia
PubMed · Cochrane Database of Systematic Reviews · Science review · 2019
Source accessed
- Randomized Cerebrolysin study in Alzheimer's disease
PubMed · Journal of Neural Transmission · Randomized trial · 2002
Source accessed
- Peptide profile of an Internet-obtained Cerebrolysin sample
PubMed · Drug Testing and Analysis · Reference · 2015
Source accessed
- Comparison of Cerebrolysin with other peptide preparations
PubMed · Journal of Medical Life · Reference · 2024
Source accessed
- 2026 Prohibited List
World Anti-Doping Agency · Anti-doping · 2026
Source accessed